InSphero Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Private

  • Employees
  • 73

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $26.9M

  • Investors
  • 9

InSphero General Information

Description

Developer of 3D-cell-based assay and scaffold-free 3D organ-on-a-chip technology designed to deliver biologically relevant insights for in vitro testing. The company's technology helps identify drugs and toxic liabilities with predictive power at early development stages, enabling biotechnological industries to make proper preclinical decisions, reduce development costs and shorten time to reduce animal use in testing.

Contact Information

Website
www.insphero.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Wagistrasse 27A
  • 8952 Schlieren
  • Switzerland
+41 044
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Vertical(s)
HealthTech
Corporate Office
  • Wagistrasse 27A
  • 8952 Schlieren
  • Switzerland
+41 044

InSphero Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

InSphero Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Later Stage VC 31-Mar-2023 $26.9M Completed Generating Revenue
10. Debt - General 01-Mar-2021 Completed Generating Revenue
9. Later Stage VC 13-Jun-2018 Completed Generating Revenue
8. Grant 21-Oct-2015 Completed Generating Revenue
7. Secondary Transaction - Private 12-Oct-2015 Completed Generating Revenue
6. Later Stage VC (Series C) 08-Jul-2015 Completed Generating Revenue
5. Early Stage VC (Series B) 13-Jun-2013 Completed Startup
4. Grant 27-Mar-2012 Completed Startup
3. Early Stage VC (Series A) 02-Aug-2010 $1.43M $2.71M Completed Startup
2. Early Stage VC 01-Jan-2009 $1.14M $1.28M Completed Startup
To view InSphero’s complete valuation and funding history, request access »

InSphero Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Ordinary Shares
Ordinary Shares
Ordinary Shares
Ordinary Shares
Ordinary Shares
Ordinary Shares 45,460 $1.077644 $11.85 $11.85 1x $11.85 11.48%
Ordinary Shares 38,234 $1.077644 $36.64 $36.64 1x $36.64 9.66%
To view InSphero’s complete cap table history, request access »

InSphero Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of 3D-cell-based assay and scaffold-free 3D organ-on-a-chip technology designed to deliver biologically releva
Biotechnology
Schlieren, Switzerland
73 As of 2023

Orlando, FL
 

Leiden, Netherlands
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

InSphero Competitors (22)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Hesperos Venture Capital-Backed Orlando, FL
Ncardia Venture Capital-Backed Leiden, Netherlands
Cellesce Formerly VC-backed Cardiff, United Kingdom
Aspect Biosystems Venture Capital-Backed Vancouver, Canada
Nagi Bioscience Venture Capital-Backed Saint-Sulpice, Switzerland
You’re viewing 5 of 22 competitors. Get the full list »

InSphero Patents

  • 67

    Total Documents Applications and Grants

  • Total Patents Families

  • 40

    Granted

  • 8

    Pending

  • Expiring in next 12 mo

InSphero Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4433572-A1 Microfluidic device Pending 17-Nov-2021
EP-3981401-A1 Pharmaceutical combination for the treatment and/or prevention of diabetes comprising a calcium channel blocking agent and an incretin mimetic Inactive 06-Oct-2020
EP-4225296-A1 Pharmaceutical combination for use in the treatment and/or prevention of diabetes Pending 06-Oct-2020
US-20230330188-A1 Pharmaceutical combination for use in the treatment and/or prevention of diabetes Pending 06-Oct-2020
US-20210245945-A1 Transport device with an inner container Active 06-Sep-2018 B01L9/523
To view InSphero’s complete patent history, request access »

InSphero Executive Team (19)

Name Title Board Seat
Jan Lichtenberg Ph.D Co-Founder, Chief Executive Officer & Board Member
Jürg Gysi Ph.D President & Chairman
Filip Henzler Chief Financial Officer
Armin Wolf Ph.D Co-Chief Scientific Officer
Madhu Nag Ph.D Co-Chief Scientific Officer
You’re viewing 5 of 19 executive team members. Get the full list »

InSphero Board Members (10)

Name Representing Role Since
Beat Schillig Self Board Member
Jan Lichtenberg Ph.D InSphero Co-Founder, Chief Executive Officer & Board Member
Jürg Gysi Ph.D InSphero President & Chairman
Thomas Pfisterer Self Board Member
You’re viewing 4 of 10 board members. Get the full list »

InSphero Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

InSphero Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Beat Schillig Angel (individual) Minority
SICTIC Angel Group Minority
ZEISS Ventures Corporate Venture Capital Minority
Jürg Gysi Angel (individual) Minority
Occident Group Venture Capital Minority
You’re viewing 5 of 9 investors. Get the full list »

Ready to get started?

Request a free trial

InSphero FAQs

  • When was InSphero founded?

    InSphero was founded in 2009.

  • Who is the founder of InSphero?

    Jan Lichtenberg Ph.D and Wolfgang Moritz Ph.D are the founders of InSphero.

  • Who is the CEO of InSphero?

    Jan Lichtenberg Ph.D is the CEO of InSphero.

  • Where is InSphero headquartered?

    InSphero is headquartered in Schlieren, Switzerland.

  • What is the size of InSphero?

    InSphero has 73 total employees.

  • What industry is InSphero in?

    InSphero’s primary industry is Biotechnology.

  • Is InSphero a private or public company?

    InSphero is a Private company.

  • What is the current valuation of InSphero?

    The current valuation of InSphero is .

  • What is InSphero’s current revenue?

    The current revenue for InSphero is .

  • How much funding has InSphero raised over time?

    InSphero has raised $63.5M.

  • Who are InSphero’s investors?

    Beat Schillig, SICTIC, ZEISS Ventures, Jürg Gysi, and Occident Group are 5 of 9 investors who have invested in InSphero.

  • Who are InSphero’s competitors?

    Hesperos, Ncardia, Cellesce, Aspect Biosystems, and Nagi Bioscience are some of the 22 competitors of InSphero.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »